

## Review Form 1.6

Journal Name:	<a href="#">Journal of Pharmaceutical Research International</a>
Manuscript Number:	Ms_JPRI_76882
Title of the Manuscript:	Seroprevalence of anti-SARS-cov-2 antibodies in covid-19 patients in Hyderabad, Pakistan
Type of the Article	Original Research Article

### General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://peerreviewcentral.com/page/manuscript-withdrawal-policy>)

### **PART 1:** Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b><u>Compulsory</u></b> REVISION comments	<ul style="list-style-type: none"><li>- Scientific names should write correct.</li><li>- SARS CoV-2, 2019-nCoV and COVID-19 could not use as same mean. It should correct in all article.</li><li>- There is not enough reference for some important sentences in the introduction part.</li><li>- In the material method part, information on the status of the cases (asymptomatic, moderate, or non-pneumonia) is not provided, as indicated in the purpose of the article.</li><li>- It is not clear that how many days kept the samples and where (in the Study design and participants part).</li><li>- The material method section of the article should include the experimental design of the study. This section contains general information only. Therefore, it is recommended to remove this part.</li><li>- Specimen Collection and Shipment part contains irrelevant information to this article. Information about the collected samples has already been given in the "Study design and participants" part. Therefore it is recommended to remove this part.</li><li>- There is a copy paste mistake "as well as the Roche's SARS-CoV2 antibody test in the U.S, which has a specificity of 99.8% and 100% sensitivity<sup>3</sup> (14 days post-PCR confirmation)".</li><li>-</li></ul>	<ol style="list-style-type: none"><li>1. Scientific names are correct and written in same manner in the entire manuscript.</li><li>2. References are included in the introduction.</li><li>3. Material and methods section is revised as per suggestion.</li><li>4. The samples are analyzed as soon as possible also this information add to the manuscript.</li><li>5. Material and methods section is revised as per suggestion. The general information is not necessarily removed from the manuscript as per recommendation.</li><li>6. This part is also removed as per recommendation.</li><li>7. The mistake is also corrected as per suggestion.</li><li>8. The manuscript language is revised.</li></ol>
<b><u>Minor</u></b> REVISION comments		
<b><u>Optional/General</u></b> comments	The Manuscript should write according to scientific writing. The Manuscript is not well understood.	

Review Form 1.6

PART 2:

	<b>Reviewer's comment</b>	<b>Author's comment</b> <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<b>Are there ethical issues in this manuscript?</b>	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	There is not any the ethical issues in this manuscript and the study is approved by ethical committee of Isra University which is also provided in the section of ethical approval and consent to participate.